Lifecore Biomedical (LDE) AI Stock Analysis
Lifecore Biomedical
(Frankfurt:LDE)
No summary available
Lifecore Biomedical (LDE) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 242.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,841
- Price to Earnings (P/E)
- -5.8
- Beta (1Y)
- 1.15
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Germany
- Employees
- 382
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Lifecore Biomedical Business Overview & Revenue Model
Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services i...
Lifecore Biomedical Earnings Call Summary
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Lifecore reaffirmed 2026 guidance of $120–125 million in revenue and $20.5–25.0 million in adjusted EBITDA, noting H2 midpoint expectations of roughly $65 million in revenue and $13 million in adjusted EBITDA with a Q4-weighted back half and a step-up in CDMO/aseptic revenue; Q2 results were $34.2M revenue, $12.1M gross profit, $8.0M SG&A, $8.6M adjusted EBITDA and a $6.2M net loss ($0.19/share), while the six‑month totals were $57.4M revenue, $16.5M gross profit, $15.9M SG&A, $9.6M adjusted EBITDA and a $21.1M net loss ($0.61/share). Liquidity at quarter end was ~$38.8M (cash $17.2M + revolver availability $21.6M), free cash flow for the year is targeted at ~$7–10M, and the company has achieved cumulative SG&A/R&D savings of $16.2M since late‑2024 with SG&A expected to trend to about $6M/quarter (ex‑one‑time items) in the back half. Looking to the mid/long term, Lifecore reiterated a 12% revenue CAGR to 2029, a >25% adjusted EBITDA margin target by 2029, ~60% installed capacity utilization by 2029, and specific program/demand metrics including a doubling of committed fill/finish demand beginning in 2027 (and >200% increase in 2028 vs 2026), 11 development programs potentially commercializing by end‑2028, and recent business development wins (6 in Q2, 9 YTD, 13 LTM) with >60% of competed opportunities being late‑stage or site transfers.
Lifecore Biomedical Risk Analysis
Lifecore Biomedical disclosed 30 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksLifecore Biomedical Peers Comparison
Overall Rating
IRWD64Neutral
DERM55Neutral
CPIX47Neutral
BIOA44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IRWD | 64Neutral | $578.34M | 4.40 | -57.40% | ― | 26.19% | ― |
| DERM | 55Neutral | $145.92M | -22.89 | -20.23% | ― | 20.89% | 40.71% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CPIX | 47Neutral | $70.27M | -6.56 | -47.10% | 29.55% | -25.68% | -244.92% |
| BIOA | 44Neutral | $269.41M | -2.47 | -28.99% | ― | 168.06% | -6.76% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:LDE | Lifecore Biomedical, Inc. | 5.70 | -0.35 | -5.79% | |
| IRWD | Ironwood Pharmaceuticals | 3.50 | 1.63 | 87.17% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 4.69 | 2.63 | 127.45% | |
| SXTC | China Sxt Pharmaceuticals | 3.25 | -1703997.05 | -100.00% | |
| DERM | Journey Medical Corporation | 5.17 | -3.83 | -42.56% | |
| BIOA | BioAge Labs, Inc. | 5.87 | -1.60 | -21.42% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.